Monitor for topline Phase 3 CATT1 data in 2H 2026, which will be a critical catalyst for the stock. The current cash position provides sufficient runway to reach this milestone.
Price Chart
Executive Summary
vTv Therapeutics released an investor presentation disclosing that its lead asset, Cadisegliatin, is in Phase 3 development for type 1 diabetes, with topline data expected in the second half of 2026. The company highlighted a strong balance sheet with $118.5 million in cash, providing runway past the data readout. No new financial guidance or clinical results were provided.
Key Facts
- Cadisegliatin is in Phase 3 development for type 1 diabetes with topline CATT1 data targeted for 2H 2026
- Company has $98.5M cash as of 9/30/2025 plus $20.0M received on 2/2/2026, totaling $118.5M
- Cadisegliatin has FDA Breakthrough Therapy Designation for treatment of T1D
- Presentation contains forward-looking statements about future operations and financial performance
Financial Impact
$118.5 million cash runway through 2H 2026
Risk Factors
- Clinical trial failure risk for Cadisegliatin
- Dependence on successful Phase 3 results for company valuation
- Dilution risk if additional funding is needed beyond current runway
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001641489-26-000005 |
| Document: vtvt-20260226.htm | 0001641489-26-000005 |
| Document: 0001641489-26-000005-index-headers.html | 0001641489-26-000005 |
| Document: 0001641489-26-000005-index.html | 0001641489-26-000005 |
| Document: 0001641489-26-000005.txt | 0001641489-26-000005 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 10, 2026 16w ago | DEFA14A | $31.59 $33.35 | ▲ +5.57% | ▲ +1.18% | $31.34 (−0.79%) |
May 8, 2026 20w ago | Press Release | $30.46 $34.39 | ▲ +12.90% | ▲ +8.51% | $31.34 (+2.89%) |
Mar 10, 2026 29w ago | Press Release | $35.10 $32.94 | ▼ −6.15% | ▼ −17.68% | $31.34 (−10.71%) |
Feb 26, 2026 31w ago | 8-K | $39.32 $35.50 | ▼ −9.72% | ▼ −17.47% | $31.34 (−20.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access